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Introduction and Purpose. Monitoring solid tumor growth and metastasis in small animals is important for cancer research.
Noninvasive techniques make longitudinal studies possible, require fewer animals, and have greater statistical power. Such
techniques include FDG positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and optical imaging,
comprising bioluminescence imaging (BLI) and ﬂuorescence imaging (FLI). This study compared the performance and usability
of these methods in the context of mouse tumor studies. Methods. B16 tumor-bearing mice (n = 4 for each study) were used
to compare practicality, performance for small tumor detection and tumor burden measurement. Using RETAAD mice, which
develop spontaneous melanomas, we examined the performance of MRI (n = 6 mice) and FDG-PET (n = 10 mice) for tumor
identiﬁcation. Results. Overall, BLI and FLI were the most practical techniques tested. Both BLI and FDG-PET identiﬁed small
nonpalpable tumors, whereas MRI and FLI only detected macroscopic, clinically evident tumors. FDG-PET and MRI performed
well in the identiﬁcation of tumors in terms of speciﬁcity, sensitivity, and positive predictive value. Conclusion.E a c ho ft h ef o u r
methods has diﬀerent strengths that must be understood before selecting them for use.
1.Introduction
Studies in living animals are critical to oncology research,
and many experimental models have been exploited for
drug development and basic studies [1, 2]. Fast-growing
tumors can be generated in mice by orthotopic or ectopic
implantation of tumor cell lines. However, models exhibiting
spontaneous oncogenesis better mimic human disease there-
fore, oncogene-driven or chemically induced tumor models
havecomeintousemorerecently[3,4].Inbothspontaneous
and transplanted tumor models, the most common readouts
are primary tumor growth and metastatic spread, but accu-
rate measurement of these parameters is challenging. Unlike
necropsy, noninvasive imaging techniques could oﬀer an
idealsolutionastheyallowmeasurementoftumorburdenin
the whole body without the need to sacriﬁce the animal. This
makeslongitudinalstudiespossible,simultaneouslyreducing
the number of animals required and producing more robust
data. These technologies are also sensitive and accurate
enough to detect microscopic nodules, whose importance in
human disease prognosis is increasingly recognized [5, 6].
Several imaging techniques have recently become avail-
ableforsmallanimals[7].Theseinclude2-deoxy-2-[18F]ﬂu-
oro-D-glucose positron emission tomography (FDG-PET)
[8], T2-weighted magnetic resonance imaging (T2W-MRI)
[9], and optical imaging, encompassing bioluminescence
imaging (BLI) [10] and ﬂuorescence imaging (FLI) [11].
BothFDG-PETandT2W-MRIareusedclinicallyinhumans,
whereas optical imaging is speciﬁcally used for research
and preclinical studies. While each method has its own2 International Journal of Molecular Imaging
advantages, a detailed side-by-side comparison of their use
for tumor imaging has yet to be carried out.
The purpose of the present study is to compare practi-
cality and performance of these four imaging techniques in
the context of mouse tumor studies. Speciﬁcally, we assessed
four diﬀerent parameters, namely, practicality, performance
for small tumor detection, performance for tumor burden
measurement, and performance for tumor identiﬁcation.
The ﬁrst two parameters were comparatively assessed across
all four imaging technologies. The performance for tumor
burden measurement was conducted speciﬁcally for optical
methods, since they are well adapted for this purpose.
Conversely, the performance for tumor identiﬁcation was
compared only between MRI and FDG-PET, since optical
methodscannotbeappliedforthispurposeincurrenttumor
models.
We used two murine melanoma models to conduct the
proposed comparisons. The B16 transplanted tumor model
is well-deﬁned and oﬀers a high level of ﬂexibility [2]. B16
cells can be modiﬁed to express the transgenes required for
detection by optical imaging, followed by injection of these
cells into the animal by diﬀerent routes to produce either
subcutaneous or pulmonary lesions [2]. Tumor onset is pre-
dictable, so nodules can be tracked from their microscopic
stage, making this model ideal to assess the practicality and
performance of each technique for small tumor detection
and tumor burden measurement. The second model is the
RETAAD mouse which spontaneously develops melanoma
tumorsandmetastases[3].Incontrasttotransplantedtumor
models, RETAAD tumors may arise at any location in the
skin(cutaneousmelanomatumors)andinternalorgans(vis-
ceralmetastases).Thismodelis,therefore,particularlysuited
for the assessment of the performance of imaging techniques
intumoridentiﬁcation,asitmakesitpossibletocalculatethe
speciﬁcity, the sensitivity, and the positive predictive value
for tumor detection. Tumors in spontaneous models usually
do not express reporter genes and are, therefore, not suited
for optical imaging technologies. Therefore, we have used
this model to compare FDG-PET and T2W-MRI.
2.MaterialsandMethods
2.1. Cell Lines. Stably transfected B16 cells were used for
detection by optical imaging techniques. B16-F10-luc cells
(Xenogen, Alameda, Calif, USA) express ﬁreﬂy luciferase
(sequence from pGL3, Promega) under the control of the
SV40 promoter. B16-F10-RFP cells express DsRed2 under
the control of the CMV promoter [11, 12].
2.2. Animals. All studies were approved by the Institutional
Animal Care and Use Committee of the Biological Resource
CenterandofSinghealth.C57Bl/6micewereinoculatedsub-
cutaneously or intravenously with 105 B16-F10-luc or B16-
F10-RFP cells. RETAAD mice were generated as previously
described [3].
2.3. Clinical Examination. B16-injected mice were examined
by palpation at the site of injection. Two perpendicular dia-
meters (d1 ≤ d2) of the tumor were then measured using
caliper, and were used to calculate the tumor volume (V)
(V = 4/3 ·π ·d2
1 ·d2/8).
2.4. Necropsy Analysis. Prior to necropsy, the investigator
was unaware of the results of the imaging scans, rendering
the two analyses independent. Mice injected subcutaneously
with B16 cells were examined at the injection site. Animals
injected intravenously with B16 cells were examined for their
lungs and peritoneal cavity as described [2]. RETAAD mice
develop tumors spontaneously with widespread metastases,
so they were subjected to more extensive necropsy. For
each mouse, a necropsy diagram was ﬁlled to document the
location, size, and morphology of nodules.
2.5. 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography
Scan (FDG-PET). Four mice subcutaneously injected with
B16 cells were used to determine the smallest detectable
tumor. Ten RETAAD mice were used to assess performance
in tumor identiﬁcation.
After fasting overnight, mice were prewarmed to 37◦C,
and approximately 5.5MBq of FDG (0.6mM) (Department
of Nuclear Medicine, Singapore General Hospital) was
administered intraperitoneally [14]. Mice were then main-
tained at 37◦C throughout the one-hour uptake period [14].
Micro-PET imaging was performed using a R4 microPET
scanner (Concordes Microsystems Inc.) with a ring diameter
of 26cm, 7.8cm axial ﬁeld of view and an average intrinsic
spatial resolution of 1.75mm. Under isoﬂurane anesthesia,
mice were subjected to 15 minutes of acquisition. For
image reconstruction, an energy window of 350–700keV
and a coincidence timing window of 6ns were used. Two-
dimensional histograms by Fourier rebinning and image
reconstruction by ﬁltered backprojection were used. The
image data were corrected for nonuniformity of the scanner
response, dead time count losses, and physical decay to the
time of injection. No correction was applied for attenuation,
scatter, or partial-volume averaging, as these parameters are
n o tc r i t i c a lf o rm o u s em o d e l s[ 15].
In the reconstructed images, tumors were identiﬁed as
regions of high uptake in study animals that were absent
from images of control mice. To allow quantitative image
analysis, regions of interest (ROI) were manually drawn over
areas of high uptake. Within these regions, counting rates
were converted to standardized uptake values (SUVs) using
a system calibration factor derived from the imaging of a
mouse-size water-equivalent phantom containing 18F.
2.6. T2-Weighted Magnetic Resonance Imaging (T2W-MRI).
Four mice subcutaneously injected with B16 cells were used
to determine the smallest detectable tumor. Six RETAAD
mice were used to assess performance in tumor identiﬁca-
tion.
Data were acquired at the Singapore Bioimaging Con-
sortium on a 9.4T MRI scanner (Varian, Palo Alto, Calif,
USA) using a transmit-receive volume RF coil. A multislice
2D fast spin echo with periodically rotated parallel lines
withenhancedreconstruction(PROPELLER)pulsesequence
[16] was used to give high image quality and robustness toInternational Journal of Molecular Imaging 3
motion. Scans were performed for the brain and abdominal
regions under isoﬂurane anesthesia. Brain scans were con-
ducted using the following parameters: repetition time (TR)
= 4000ms; eﬀective echo time (TE) = 51ms; echo spacing
(ESP) = 6.4ms; echo train length (ETL) = 16; ﬁeld-of-view =
25.6 × 25.6mm; blade matrix = 256 × 16; number of blades
= 32; reconstructed matrix = 256 × 256; slice thickness =
1mm;slicegap =0.5mm;slices =5;averages =1;orientation
= axial; readout bandwidth = 208kHz and acquisition time
= 2min 16s. For the abdomen, several changes were made
to accommodate the shorter T2 so that, TE = 20ms; ESP =
5.0ms;ETL =8;bladematrix =128×8;reconstructedmatrix
= 128 × 128; slice gap = 0.2mm. The resulting data were
used to reconstruct images as described [17]. Tumors were
identiﬁed as highly contrasted masses or nodules that were
present in study animals but absent from control mice.
2.7. Bioluminescence Imaging (BLI). For all BLI experiments,
the B16-luc cell line was used. Studies to determine the
smallest detectable tumors, accuracy for tumor burden
measurement, and tissue attenuation used four, four, and
six mice, respectively, each subcutaneously injected with B16
cells. To further demonstrate the possibility to use BLI for
accurate followup of tumor growth (as shown in Figure 5),
4 unshaved mice were injected subcutaneously with B16
cells and another 4 were injected intravenously. For other
experiments, mice were shaved as indicated in the ﬁgure
legends.
15–25 minutes before imaging, mice were injected
intraperitoneally with 200μL of D-luciferin (15mg/mL
in PBS) as described [10] and then anesthetized using
isoﬂurane. For in vitro imaging, cells were plated in PBS in
ﬂat-bottomed 96 well plates before D-luciferin was added
to a ﬁnal concentration of 1.5mg/mL. Immediately after
necropsy, some tumors were excised and imaged ex vivo on
tissue culture plates. These plates were scanned for 5 to 40
seconds, whereas mice were scanned for 30 to 60 seconds
using the IVIS Spectrum photon-counting device optical
imaging system (Xenogen, Alameda, Calif, USA). Regions of
interest were drawn and quantiﬁed using the Living Image
software version 2.5. Bioluminescence signal was reported as
total light emission within the region of interest (photon/s).
Speciﬁc signal was calculated as the ratio of bioluminescent
signalin theregion ofinteresttothebioluminescent signalin
a background region containing no cells or tumors. A signal
was deﬁned as positive when it was greater than the sum of
the mean background signal plus 2 standard deviations of
the background signal.
2.8. Fluorescence Imaging (FLI). For all FLI experiments,
the B16-RFP cell line was used. Studies to determine the
smallest detectable tumors, accuracy for tumor burden
measurement, and tissue attenuation used four, four, and
six mice, respectively, each subcutaneously injected with B16
cells.
For in vivo imaging, animals were anesthetized using
isoﬂurane and some mice were shaved as indicated in the
ﬁgure legends. For in vitro imaging, cells were plated in PBS
in ﬂat-bottomed 96-well plates. Immediately after in vivo
imaging, some tumors were excised at necropsy and imaged
ex vivo on tissue culture plates. Plates or mice were scanned
for 0.1 to 1 seconds using the IVIS Spectrum photon-
counting device optical imaging system (Xenogen, Alameda,
CA) with ﬁlters for red ﬂuorescence (excitation 535nm,
emission 600nm) and background ﬂuorescence (excitation
465nm, emission 600nm). Regions of interest were drawn
and quantiﬁed using Living Image software version 2.5. Flu-
orescence background was subtracted according to the man-
ufacturers’ instructions. Fluorescence signal was reported as
light conversion eﬃciency. Speciﬁc signal was reported as the
ratio of the ﬂuorescence signal in the region of interest to
the ﬂuorescence signal in a background region containing no
cells or tumors. A signal was deﬁned as positive when it was
greater than the sum of the mean background signal plus 2
standard deviations of the background signal.
2.9. Statistical Analysis. BLI and FLI speciﬁc signals (signal-
to-noise ratio) for single time point experiments were
compared using the Mann-Whitney test.
Tumor growth curves were compared using a nonpara-
metric test according to [13].
Tumor optical imaging signal and tumor volume were
compared using Spearmann correlation.
The speciﬁcity was deﬁned as (number of sites where
no tumor was found)/(total number of sites without tumor
conﬁrmed at necropsy), where the total number of possible
sites for tumor growth in each RETAAD mouse was 14
(cheeks, neck, genitals, ﬂanks, forelimbs, hind limbs, and
peritoneum, each time on the left or right side).
The positive predictive value was deﬁned as (number of
tumors detected by imaging and conﬁrmed at necropsy)/
(total number of tumors detected by imaging).
The sensitivity for tumor identiﬁcation was deﬁned as
follows: (number of tumors detected by imaging and conﬁr-
m e da tn e c r o p s y ) / ( t o t a ln u m b e ro ft u m o r so b s e r v e da tn e -
cropsy).
3. Results
3.1. Practicality. Three parameters were taken into account:
animal preparation, time for analysis, and ease of access to
the technology (Table 1).
All techniques required anesthesia of the animal by
isoﬂurane inhalation, taking approximately 4 minutes per
mouse. The additional tracer injection and preincubation
time for FDG-PET resulted in at least 3-fold longer prepa-
ration time per animal compared to the other techniques.
Shaving requires 10 minutes per animal, and while there has
been debate on whether it can be omitted for optical imaging
[11], we found it to be dispensable for BLI (see below).
We next compared the time needed for image acquisition
and analysis. Because devices diﬀer, we selected widely used
platforms for comparison: IVIS Spectrum (Xenogen) for
optical imaging, R4 microPET (Concordes Microsystem)
for FDG-PET, and 9.4T MRI (Varian) for T2W-MRI. The
main diﬀerences in practicality between technologies were
highlighted by the ease of scale-up to larger groups of4 International Journal of Molecular Imaging
Table 1: The process of analyzing tumor burden in whole mice.
FDG-PET T2W-MRI BLI FLI
Operating costs Around ﬁve US dollars per time point per animal for all techniques
Equipment costs ∼600,000US dollars 1 to 2 million US dollars <500,000US
dollars <500,000US dollars
Mouse preparation
Anesthesia, tracer
injection, incubation
time and positioning
Anesthesia, set up of monitoring,
prescan for positioning
Anesthesia,
substrate injection,
incubation time,
shaving (optional),
and positioning
Anesthesia, shaving
and positioning
Mouse preparation time 1h 30min 30min 20min 5min
Scanning time 15min/3D scan 30min/2D multislice scan/area
(2 areas scanned per mouse)
1s–2min/picture
1t o1 0
pictures/scan
1s–30s/picture1to
10 pictures/scan
Data analysis Requires expertise Requires expertise Straightforward Straightforward
Dataanalysistime 1h 1h30min 20min 20min
T otaltime1animal 3h 3h 1h 30min
Total time 10 animals 13h 30h 2h 1h
animals. For example, the IVIS Spectrum allows parallel
imaging of up to 5 mice, taking as little as 2 minutes to
complete all the scans. In contrast, both FDG-PET and
T2W-MRI can typically image only one mouse at a time
(maximum 2 in some settings), taking at least 15 minutes
per scan. Overall, this meant that optical scanning of 10 mice
couldbecompletedin1-2hours,whereasFDG-PETorT2W-
MRI would take 13–30 hours.
The last parameter considered was cost and availability.
Each technique has low reagent and consumable costs of
around ﬁve US dollars per scan per animal. FDG can usually
be obtained as surplus material from nuclear medicine
departments or comes at a low cost compared to other
PET reagents. Equipment for optical imaging is accessible
in many research institutes and costs less than ﬁve hundred
thousand US dollars, with the PET scanner costing around
six hundred thousand US dollars. MRI scanners are most
expensive, costing one to two million US dollars.
Overall BLI and FLI are the most practical techniques
and are particularly suitable for large studies requiring high
throughput imaging.
3.2.DeterminationoftheSmallestDetectableTumor. TheB16
melanoma model allowed us to assess the smallest tumors
that could be accurately detected by the various techniques.
Four mice per technique were injected subcutaneously with
105 B16 cells, resulting in tumor growth at the injection site
[2]. These tumors were clinically undetectable up to day 10
after injection, but were evident at necropsy. After day 10,
tumors become macroscopic (2mm diameter and above)
and were measured in living animal with a caliper.
BLI and FDG-PET detected nonpalpable tumors
(<1mm), whereas the smallest tumors detected by T2W-
MRI and FLI were 1mm and 2mm diameter, respectively
(Figure 1). BLI detected microscopic tumors as early as 1 day
after subcutaneous injection (Figure 1(c)) when the nodules
were too small to be detected even at necropsy. While this
means that their presence could not be conﬁrmed either
visually or histologically, these tumors were actively growing,
increasing their BLI signal and could indeed be identiﬁed
at necropsy by day 2 (data not shown). Overall, BLI and
FDG-PET are applicable for in vivo detection of microscopic
tumors, whereas T2W-MRI and FLI are only applicable to
palpable tumors.
Both optical imaging techniques can be used to follow
transplanted tumor growth. To carry out a detailed compar-
ison, we selected two B16-luc and B16-RFP clones showing
equivalent performance for in vitro imaging (Figure 2(a))
with similar growth rates in vitro (not shown) and in vivo
(Figure 2(b)). At day 1, 2, 3 and 5 after injection, only
BLI detected nonpalpable tumors (Figure 2(c)). At further
time points, the tumor-speciﬁc signal detected by BLI was
signiﬁcantly greater than that seen by FLI for tumors of
equivalentsize(Figure 2(c)).Bothtechniquesmay,therefore,
be used to follow small macroscopic tumors, but only BLI
provides data at the microscopic stage.
3.3. Eﬀects of Tissue Attenuation on Small Tumor Detection
by Optical Imaging. We investigated the higher sensitivity
observed for BLI compared to FLI when performed in vivo.
One hypothesis is that tissue attenuation aﬀects FLI more
than BLI. Attenuation occurs when tissues around the tumor
absorb some of the imaging excitation and emission signal,
autoﬂuoresce, leading to a reduction in the signal to noise
ratio.
To test this hypothesis, we measured signal reduction by
comparing ex vivo (Figure 3(a))a n din vivo (Figure 3(b))
signals after tumor excision. The signal measured in vivo
on shaved mice was reduced 3-fold for BLI and 14-fold for
FLI compared to the signal of tumors ex vivo after excision
(Figure 3(b)), conﬁrming the hypothesis that FLI is more
prone to tissue attenuation. To address the contribution of
mouse hair to further signal attenuation, we imaged tumor-
bearing mice before and after shaving. Again, the FLI signalInternational Journal of Molecular Imaging 5
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Figure 1: Detection of tumors by in vivo imaging. B16 melanoma cells were subcutaneously injected into shaved C57Bl/6 mice (n = 4 mice
for each technique). Mice were repeatedly imaged by: (a) FDG-PET, (b) T2W-MRI, (c) BLI, and (d) FLI. For each technique, a representative
mouse is shown, and the smallest detected tumor is reported. Arrows indicate tumors. SUV, standardized uptake value.
(over than 400 fold reduced) was more prone to attenuation
than the BLI signal (70 fold reduction) (Figure 3(c)).
In summary, tissue and hair surrounding the tumor
signiﬁcantly reduced the ability of FLI to detect small tumors
in vivo. This tissue attenuation eﬀect is higher for FLI than
for BLI.
3.4. Accuracy of Optical Imaging for Measuring Tumor Burden
In Vivo. Traditionally, caliper measurements are used to
calculate tumor volume. We compared tumor volumes
estimated in vivo by BLI and FLI, to those calculated by
caliper measurements and found a good correlation between
these two techniques (Figure 4). Therefore, optical imaging
is appropriate to assess tumor burden.
BLI has demonstrated an ability to detect microscopic
tumors and to estimate tumor volumes in vivo with good
accuracy. To further explore the power of the technique
we injected unshaved mice either subcutaneously or intra-
venously with B16-luc cells and imaged them repeatedly.
As expected, BLI detected subcutaneous tumors earlier than
clinical examination (Figure 5(a)). Moreover, the biolumi-
nescent signal follows a characteristic Gompertzian curve as6 International Journal of Molecular Imaging
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Figure 2: Tumor growth monitored in vivo by optical imaging. (a) Signal to background ratio is similar for BLI (B16-luc, left) and FLI
(B16-RFP, right) in vitro. Results are shown as the mean and SD of 4 replicate wells from 2 independent experiments. (b) B16-luc and B16-
RFP tumors grow equally in vivo. Following subcutaneous injection of cell lines into mice (n = 4 mice for each cell line), tumor volume
was calculated from caliper measurements. Four tumors were measured for each cell line. NS, no signiﬁcant diﬀerence between B16-luc and
B16-RFP (P>0.05, test according to [13]). (c) BLI is more sensitive for tumor detection in vivo. B16-luc or B16-RFP cells were injected
subcutaneously. Mice (n = 4 mice each for BLI and FLI) were shaved and imaged. Four tumors were measured for each cell line. The dotted
line represents the detection threshold calculated based on control tumors not expressing the relevant reporter gene. ∗, signiﬁcant diﬀerence
between B16-luc and B16-RFP (P<0.05, test according to [13]).
expected for tumor growth [18], therefore more accurately
reﬂecting the biology of the tumor compared to caliper
measurements. BLI detected a signal following intravenous
injection of B16-luc only after a few minutes, which likely
reﬂects the initial trapping of the injected cells in the lung.
By day 4 most of these cells were cleared and the BLI signal
dropped, only to increase again as tumor growth occurred
in the lungs, peritoneal cavity and at the point of injection
(Figure 5(b)) .T h e s et u m o r sw e r ec o n ﬁ r m e db yn e c r o p s y
(data not shown). BLI can, therefore, be used in shaved or
unshaved mice for quantitative followup of tumor growth at
both cutaneous and internal sites.
3.5. Speciﬁcity, Sensitivity, and Predictive Value of FDG-PET
and T2W-MRI in a Spontaneous Tumor Model. Spontaneous
or carcinogen-induced tumor models are increasingly used
for cancer research. In these animals, a variable number of
tumors arise in a range of locations over a less predictable
time course. Macroscopic tumors are then assessed at
necropsy, which is considered ground truth. The need to
sacriﬁce the animal for information is a disadvantage of such
models, but to replace necropsy by in vivo imaging, three
criteria must be met. Firstly, the technique must correctly
predict the absence of tumors at normal sites and for
nontumorbearingmice(speciﬁcity).Secondly,thetechniqueInternational Journal of Molecular Imaging 7
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Figure 3: Mouse tissue attenuation is stronger for FLI than BLI. (a) B16-luc and B16-RFP tumors have similar speciﬁc signal ex vivo.E x c i s e d
tumors from a total of 5 mice (n = 3f o rB L Ia n dn = 2 for FLI) were subjected to imaging. Data for individual tumors (n = 6f o rB L I
and n = 4 for FLI) and the median are shown. NS, no signiﬁcant diﬀerence (P = 0.11, Mann-Whitney test). (b) Optical signal is strongly
decreased in vivo for FLI on shaved mice. Tumors were scanned in vivo before excision. Data for individual tumors (n = 6f o rB L Ia n dn = 4
for FLI) and the median are shown. The tumors are the same as those described in (a). ∗, signiﬁcant diﬀerence (P = 0.027, Mann-Whitney
test). (c) Mouse hair strongly decreases the optical signal for FLI. B16-luc and B16-RFP tumors were imaged in vivo before and after shaving.
A representative mouse for each technique (n = 3a n dn = 2 mice analyzed for BLI and FLI, resp.) is shown.
must identify tumors accurately, with a low rate of false
positives (high predictive value). Thirdly, the technique must
be suﬃciently sensitive to detect all the tumors that necropsy
currently does. We compared the speciﬁcity, predictive value
and sensitivity of FDG-PET and T2W-MRI in the RETAAD
spontaneousmelanomamodel. During thecourseofdisease,
these mice develop tumors of various sizes in wide-ranging
anatomical locations, making the model an ideal test for the
performance of these techniques.
A representative FDG-PET scan is shown in Figure 6.
Some background is evident in the bladder, heart, and eye
regions, but this was expected due to the excretion and
circulation of the probe, and the presence of the Harderian
glands. The same eﬀect was seen in control mice, and these
regions were accordingly excluded from analysis. A total of
10 RETAAD mice and 4 control mice were independently
analyzed by FDG-PET and necropsy. Of the 28 tumors
identiﬁed by FDG-PET, 24 were conﬁrmed by necropsy
or histology, making the positive predictive value of the
FDG-PET 86%. The 4 tumors that were not conﬁrmed at
necropsy were embedded in the muscles of the back and
the limbs, sites for which histological analysis could not
be carried out. An additional ten tumors were found at
necropsy but not by FDG-PET, most likely because of low
metabolic activity. Overall, the sensitivity of FDG-PET was
70%. For speciﬁcity, only 4 tumors were predicted by FDG-
PET but could not be conﬁrmed at necropsy or histology.
Taking into account 14 possible sites for tumor growth for
each of 14 mice analyzed, the speciﬁcity of FDG-PET was
98%.
Figure 7 shows a typical T2W-MRI scan of a tumor-
bearing RETAAD mouse. A total of 6 RETAAD mice and8 International Journal of Molecular Imaging
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Figure 4: Tumor optical signal correlates with tumor volume calculated from caliper measurement. Data shown are BLI detection of
luciferase-expressing tumors (n = 22, left) and FLI detection of RFP-expressing tumors (n = 15, right) in shaved mice. Only tumors
displaying an optical signal above the background are shown. Tumors were derived from 4 mice each for BLI and for FLI. Tumors were
imagedandtumorsizesweremeasuredatvarioustimepoints.OpticalsignalandtumorvolumewerecomparedusingSpearmancorrelation.
Days after injection
F
l
u
x
(
p
h
o
t
o
n
/
s
)
Day 4 Day 9 Day 13 Day 18 Day 0
01 0 2 0
01 0 2 0
103
103
105
107
V
o
l
u
m
e
(
m
m
3
) 2.103 3000
4000
5000
6000
7000
8000
9000
10000
Color bar
Min = 3000
Max = 10000
(a)
Days after injection
Day 0 Day 4 Day 7 Day 8 Day 10 Day 11
102
104
106
0 5 10 15
F
l
u
x
(
p
h
o
t
o
n
/
s
)
3000
4000
5000
6000
7000
8000
9000
10000
Color bar
Min = 3000
Max = 10000
(b)
Figure 5: BLI detects both superﬁcial and internal tumors on unshaved mice. (a) Followup of tumor growth in vivo after subcutaneous
injection of B16-luc, using in vivo imaging and caliper measurement. A representative mouse of 4 mice is shown. The dotted line represents
the detection threshold calculated based on control areas not expressing the relevant reporter gene. (b) Followup of tumor growth using
in vivo imaging after intravenous injection of B16-luc. A representative mouse of 4 mice is shown. The dotted line represents the detection
threshold calculated based on control areas not expressing the relevant reporter gene.International Journal of Molecular Imaging 9
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4 control mice were independently analyzed by T2W-MRI
and necropsy. Twenty-two tumors were identiﬁed by T2W-
MRI, of which 21 were conﬁrmed at necropsy, making the
predictive value of T2W-MRI 95%. Five small tumors (4
out of 5 were <1mm diameter) were observed at necropsy
but not detected by imaging. The sensitivity of T2W-MRI
was, therefore, 81%. For speciﬁcity, only one tumor was
predictedbyMRIandnotconﬁrmedatnecropsy.Takinginto
account 14 possible sites for tumor growth for each of 10
mice analyzed, the speciﬁcity of T2W-MRI was 99%. Results
are summarized in Table 2.
Overall, both FDG-PET and T2W-MRI allow precise
3D visualization of tumors with good speciﬁcity, sensitivity,
and accuracy and are, therefore, highly recommended for
any study aiming at identifying tumors. Interestingly, FDG-
PET shows slightly lower sensitivity for tumor detection
than MRI, probably due to the fact that some tumors
lack the minimal metabolic activity required for detection.
Table 2: MRI and FDG-PET performance for tumor identiﬁcation
assessed using RET-AAD mice.
FDG-PET T2W-MRI
Number of mice 10 RET-AAD mice,
4c o n t r o lm i c e
6 RET-AAD mice,
4c o n t r o lm i c e
Number of tumors
(necropsy) 34 26
Number of tumors
(imaging) 28 22
Positive predictive
value 86% 95%
Sensitivity 70% 81%
Speciﬁcity 98% 99%
Therefore, FDG-PET would be the preferred choice if the
assessment of metabolic activity is desired; otherwise, MRI
is recommended (Table 2).10 International Journal of Molecular Imaging
Table 3: Summary of imaging methods used for detection of tumors in living mice.
Method Physical basis Reagents
used
Spatial
resolution
Reporter
gene
needed
Smallest
detectable
tumor
(diameter)
Analysis
time Main advantages Main disadvantages
T2W-MRI
Proton spin
relaxation
after
radiowave
emission
None 100μmN o1 m m
3h o u r s /
mouse
30
hours/10
mice
High spatial
resolution;
Anatomical
information; Gives
tumor localization,
size and morphology
Low throughput;
Respiratory motion
and high
background make
tumor detection in
lungs challenging
FDG-PET High-energy
γ rays
18Fluoro-
deoxy-
glucose
2mm No <1mm
3h o u r s /
mouse
13 hours/
10 mice
Detection of
nonpalpable tumors;
Quantiﬁes tumor cell
metabolism; Gives
tumor localization
High background in
some organs (brain,
and bladder)
prevents tumor
detection in these
regions
Biolumines-
cence
imaging
Visible light
emitted
during
chemical
reaction
D-luciferin
substrate
1t o1 0m m
dependant
on tissue
depth
Yes <1mm
1h o u r /
mouse
2h o u r s / 1 0
mice
Detection of
nonpalpable tumors;
Low background;
Relative measure of
tumor size; High
throughput
Light emission
dependant on 1/
tissue depth, 2/local
availability of
substrate reagents
(luciferin, O2,a n d
ATP)
Fluorescence
imaging
Visible light
emitted after
ﬂuorochrome
excitation
None
1t o1 0m m
dependant
on tissue
depth
Yes 2 mm
30min/
mouse
1h o u r /1 0
mice
High throughput
Light emission
dependant on tissue
depth; High
background due to
tissue
autoﬂuorescence
4. Discussion
4.1. BLI Versus FLI for Whole Body Tumor Imaging. To
compare BLI and FLI in vivo, we used tumors originating
from two diﬀerent B16 cell lines expressing ﬁreﬂy luciferase
and DsRed2, respectively. The two prototypical reporter
genes have been chosen among the most commonly used
and most eﬃcient markers at the time of writing. Results
obtained might change in the future when new reporters are
developed. With current reporter genes, both BLI and FLI
detected their respective cell lines equally well in vitro,b u t
when the cells were injected into mice and allowed to form
tumors, only BLI was able to image microscopic nodules. We
showed that this diﬀerence was due to the tissues surround-
ing the tumor duringin vivo imaging, a phenomenon known
as tissue attenuation. This is especially relevant for FLI as
the tissue can absorb and scatter ﬂuorescent light at both the
excitation and emission level. For BLI, there is no excitation
involved so only the emission is subject to attenuation. These
experiments used subcutaneous tumors, but for internal
tumors the diﬀerences between the techniques could only be
expected to be magniﬁed due to the increased optical path
through the tissues.
Despite FLI being less sensitive than BLI with the in-
strumentation we used, it has been used successfully for
whole-bodyimaginginotherstudies[11],evenwithverylow
cell numbers [19]. Such diﬀerences likely relate to variations
in experimental protocol (e.g., see [20]). In addition, FLI has
numerous applications beyond the scope of this study. For
example, labeled proteins have enabled ﬂuorescent imaging
of tumor cell mobility, invasion and angiogenesis (reviewed
in [12]). Hirakawa et al. successfully used FLI to monitor
the dissemination of very small numbers of GFP-labeled skin
tumorcellstotheproximallymphnodesofmiceinvivo[21].
Importantly,FLIissofartheonlyimaging technologytogive
single-cell resolution [22] or even subcellular resolution in
vivo [23, 24].
While each technique tested is state of the art, imaging
technologies are constantly being improved. For example,
optical techniques are being modiﬁed to permit three-
dimensional reconstruction of the bioluminescent source
and tumor localization [25]. It is even becoming possible to
combine imaging modalities using multiple fusion reporter
genes within the same animal (see, e.g., [26]).
4.2. Method of Choice for Whole-Body Tumor Imaging.
Table 3 summarizes the main features of the imaging meth-
ods, with their primary advantages and disadvantages.
Estimating the real cost of the diﬀerent technologies
is diﬃcult, and largely depends on equipment availabil-
ity. However, on the basis of equipment costs, operating
expenses, and the level of training required, optical imaging
is normally less costly than T2W-MRI and FDG-PET.International Journal of Molecular Imaging 11
While the design of the current study did not involve
the comparison of all techniques using a single tumor-
bearing animal, the B16 model is reproducible enough to
carry out a fair comparison. By using groups of at least
4 mice to perform statistical analyses, we were able to
detect some major diﬀerences between the various imaging
modalities investigated. Further studies that include larger
number of animals could be performed in order to detect
even more subtle diﬀerences between these various imaging
techniques.
Optical imaging is limited by its requirement for tumors
to express a reporter gene. This is achievable in transplanted
tumormodels,butmorechallenginginspontaneousmodels.
In fact, doing so requires generation of transgenic mice
expressing the reporter gene in the cell lineage of interest,
followedbyeithercarcinogentreatmentorintercrossingwith
an oncogene driven transgenic mouse line. This has been
achieved in some cases. For example, Vooijs et al. expressed
luciferase under a pituitary gland-speciﬁc promoter in a
model of spontaneous pituitary cancer [27]. Similarly, Lyons
et al. constructed an oncogen-driven prostate cancer model
with luciferase expression in the prostate [28]. Consistent
with our ﬁndings, both authors successfully monitored
tumor growth in vivo using bioluminescence. Therefore,
optical imaging is a valid strategy, but it is time consuming
f o rs p o n t a n e o u st u m o rm o d e l s .
In contrast to optical imaging techniques, T2W-MRI
and FDG-PET can be applied to any tumor-bearing mice,
including spontaneous tumor models. Using a B16 mouse
tumor model, we showed that T2W-MRI and FDG-PET
scans allow early detection of tumors and exhibit good
sensitivity and positive predictive value when compared to
necropsy. Results obtained with PET scanning are related
to tumor metabolism and glucose uptake by the tumors;
hence, they could vary from one tumor cell line to the other.
However, published data have shown that PET sensitivity
is high in other tumor models (see, e.g., [8]). T2W-MRI
performed slightly better, presumably because its basis is
anatomical rather than requiring tumor metabolism, as in
the case of FDG-PET. Metabolic rate assessment is a key
parameter when measuring treatment success. Indeed, in
treated cancer patients, some responsive tumors simply lose
their metabolic activity while the tumor mass is unchanged.
This typically translates into a tumor mass anatomically
identiﬁed by MRI or CT scan but FDG-PET negative. In
addition, MRI and FDG-PET are less aﬀected than optical
imaging by attenuation due to the depth of the tumor, and
both have the signiﬁcant advantage of providing precise
locations of even small nodules. As MRI and FDG-PET are
used in the clinical setting, their application in preclinical
research may help translate basic ﬁndings into clinical
studies. In this context, if whole-body metabolic imaging
is required, FDG-PET is the best option for longitudinal
followup of tumor burden and can be combined with CT
which we did not address here. T2W-MRI is better used
for speciﬁc body sections or to monitor the development
of a particular tumor over time, as it may provide contrast
and anatomical information related to location, volume,
vascularization, and invasion. Further improvements in MRI
technologies are increasing its applications. For example,
diﬀusion-weighted imaging was successfully used to detect
glioma tumors in rats [9], and more recently used for whole-
body imaging [29].
5. Conclusion
Overall, this study has highlighted how various imaging
techniques can be best used in diﬀerent types of tumor
models or to assess particular readouts. Our ﬁndings are
also likely to be easily applicable to other species including
rats. Optical imaging technologies are accessible, accurate,
and speciﬁc. BLI in particular oﬀers fast, sensitive whole-
body tumor imaging, even detecting microscopic tumors.
BLI could replace traditional caliper measurements, as it
is able and well suited to determine tumor burden in
longitudinal studies. However, the main disadvantage of
optical techniques is the requirement for tumor cells to
express a reporter gene. This has so far largely limited the use
of BLI and FLI to transplanted tumor models. However, with
time and resources, spontaneous tumor models that also
express reporter genes will become increasingly available.
In the meantime, however, this means that nonoptical
methods are preferable for tumor detection in spontaneous
models. Both available techniques have speciﬁc advantages
and disadvantages; T2W-MRI accurately reﬂects tumor
volume and morphology, but it is more time consuming,
whereas FDG-PET uniquely measures metabolic activity. In
summary, each technique represents a valuable tool to study
tumor-bearing animals, but the careful selection of the most
appropriate method will be critical to maximize the beneﬁt
of their use.
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